Navigation Links
DNA Analysis Could Help Customize Treatments for MS
Date:1/16/2008

Study suggests it could show who will respond best to interferon beta treatments

WEDNESDAY, Jan. 16 (HealthDay News) -- Genetic differences might explain why some multiple sclerosis (MS) patients respond to treatment while others don't, suggests an international study.

Starting with 206 southern European patients with relapsing-remitting MS, the most common form of the disease, the researchers compared the DNA of patients whose symptoms were reduced by interferon beta therapy to the DNA of those who experienced relapses after such therapy. They were able to identify important genetic differences between the two groups of patients.

Those differences could eventually be used to help predict which MS treatments will benefit which patients, the study authors said. MS is a neurological disorder in which nerve fiber coatings degenerate, which leads to muscle weakness and possible paralysis.

The findings appeared in the Jan. 14 online issue of the Archives of Neurology and were expected to be published in the March print issue of the journal.

"The beneficial outcomes of interferon beta therapy for patients in the relapsing-remitting phase of MS have been clearly shown," the researchers wrote. "On the other hand, the effect of this treatment is partial, and a substantial amount of patients (up to 50 percent) are not responders. Hence, in the absence of prognostic clinical, neuroradiological and/or immunological markers of response, the question remains who and when to treat when adverse effects, inconvenience and the cost of drugs are significant."

More research is needed to fully predict MS treatment outcomes based on patient DNA analysis, the researchers added.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about MS.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, Jan. 14, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Congressional Budget Office Analysis of HR971 Rejects Pharmacy Benefit Managers Bogus Claim Bill Would Cost $29 Billion Over 5 Years
2. PCMA: New CBO Analysis Confirms Independent Pharmacy Collective Bargaining Legislation Increases Costs for Consumers and Payors
3. Working with children with autistic spectrum disorder: Psychoanalysis and neurobiology
4. Uses of medications in psychoanalysis
5. First rigorous analysis defines impact of Medicare Part D
6. Updated Analysis of 2001 Epoetin Alfa Study Posted
7. Biolytix to Offer Industrial Gene Expression Analysis and Genotyping Services Using Affymetrix GeneChip(R) Technology
8. Ranking Americas Mental Health: An Analysis of Depression Across the States
9. Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntingtons Disease Program
10. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis
11. Center For Excellence to Fund Analysis of Michigan State Retiree Health Care Reforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 10, 2016 ... ... Programming (NLP) practitioner, is known locally for a series of therapeutic sessions to ... in-the-moment in their characters and in their lives. The series, known as “Mindfulness ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former ... takes a closer look at cases of TBI being managed by their members. The ... the aging population, and identifies the challenges associated with their care. , During the ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... cell disease and heart failure, today announced the pricing ... a price to the public of $0.275 per unit. ... common stock and one warrant to purchase one share ... of $0.42 per share. The warrants are exercisable six ...
(Date:2/10/2016)... Feb. 10, 2016  Silicon Biosystems Menarini Inc., ... that help uncover the biological complexities of disease ... a developer of innovative technologies for genomics research, ... aimed at enabling translational researchers to obtain high-quality ... hundred tumor and normal cells in an optimized ...
(Date:2/10/2016)... Feb. 9, 2016 CTI BioPharma Corp. ... an update regarding the clinical studies being conducted ... for pacritinib. Following the issuance of the Company,s ... clinical hold issued by the U.S. Food and ... Company received an oral communication from the FDA ...
Breaking Medicine Technology: